Continued use of nonsteroidal topical treatments: comment on the FDA talk paper.
Wolf
Ronni
R
Parish
Jennifer L
JL
Marcus
Bat Sheva
BS
Parish
Lawrence Charles
LC
D000287:Administration, Topical; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D009369:Neoplasms / Q000139:chemically induced*; D012871:Skin Diseases / Q000188:drug therapy; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus